Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622375 · ClinicalTrials.gov registry record · Phase 1
PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers
A Phase 1 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00622375 is a Phase 1 study that has completed, run by Bausch Health Americas. The registered enrollment target is 24 participants.
The verdict
NCT00622375, a Phase 1 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The current study is being conducted to evaluate the relative bioavailability and single- and multiple-dose pharmacokinetics of encapsulated mesalamine granules(eMG) in healthy subjects.
Interventions
- DRUG mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622375
The ClinicalTrials.gov registry entry for NCT00622375 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mesalamine is the first listed.
NCT00622375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00622375 about?
NCT00622375 is a clinical study titled "PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers". The current study is being conducted to evaluate the relative bioavailability and single- and multiple-dose pharmacokinetics of encapsulated mesalamine granules(eMG) in healthy subjects.
What is the current status of trial NCT00622375?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-02. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00622375?
The interventions under investigation include: mesalamine (DRUG).
Who is sponsoring clinical trial NCT00622375?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.